Condition: Bone Pain · Metastatic Malignant Neoplasm in the Bone · Plasma Cell Myeloma · Sponsor: University of Southern California
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.
This description comes directly from the study's public registry record.
Christine Duran · 323-865-0371 · Duran_C@med.usc.edu
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Los Angeles General Medical Center | Los Angeles, California, United States | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Cedars Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Emory University Hospital/Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Minnesota - Masonic Cancer Center | Minneapolis, Minnesota, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03858205